
https://www.science.org/content/blog-post/forty-years-patent-filings-look-down-upon-you
# Forty Years of Patent Filings Look Down Upon You (April 2016)

## 1. SUMMARY  
The 2016 J. Med. Chem. article mined **≈200 k US‑ and international‑patent families** (1976‑2015) to extract **1.3 M unique synthetic reactions** reported in medicinal‑chemistry claims. After heavy filtering (from an original 9 M patents and 3.3 M reactions) the authors produced a curated “med‑chem” reaction set that could be broken down into broad categories (heteroatom alkylation/arylation, acylation, deprotection, C–C bond formation, etc.) and finer sub‑types (e.g., N‑alkylation with alkyl chlorides, Suzuki‑Miyaura couplings, Boc deprotections).  

Key observations included:

* **Patent volume** rose sharply from 2001‑2010, then plateaued/declined despite a boom in biotech start‑ups.  
* **Reaction diversity** expanded through the 2000s but also leveled off after ~2010.  
* **Heteroatom alkylation/arylation** remained the largest share, though the specific reagents shifted (e.g., decline of alkyl chlorides, rise of SNAr ether formation).  
* **Acylations** moved from classic Schotten‑Baumann amide formation to modern coupling reagents (HATU, EDC, etc.) around 1996.  
* **Deprotections** became dominated by N‑Boc removal; protecting‑group formation mirrored this shift.  
* **C–C bond formation** saw the “Suzuki invasion”: aryl‑bromide couplings overtook Wittig and Knoevenagel reactions; Stille couplings rose then fell; Sonogashira peaked in the late‑80s.  
* **Oxidations** showed a clear move away from chromium reagents toward Dess‑Martin periodinane and other milder oxidants.  
* **Heterocycle construction** was highly dynamic (thiazoles, tetrazoles, benzimidazoles, click‑triazoles).  
* **Yield data** (≈460 k reactions) indicated a modest decline in median yields over the 40‑year span, attributed to higher‑throughput screening and more complex, lower‑yielding transformations.  
* **Molecular‑property trends**: increasing aromatic/heteroaryl content, rising molecular weight (flattening ~2010), cLogP peaking ~2005 then falling, and a sharp rise in rotatable bonds after the early‑1990s (linked to Suzuki couplings).

The authors concluded that the dataset offers a “real‑world” view of medicinal‑chemistry practice and hinted that future analyses might capture the impact of flow‑chemistry‑friendly reactions.

---

## 2. HISTORY  

### Patent‑filing trends (2016‑2025)  
* **US filings** continued a modest decline after 2015, falling ~8 % by 2022, largely because many companies shifted early‑stage discovery to **China, Europe, and Japan** where filing fees are lower and local IP protection is stronger.  
* **Global medicinal‑chemistry patents** grew ~15 % from 2016‑2023, driven by a surge of **Chinese biotech start‑ups** and **large‑scale collaborations** (e.g., Novartis‑CAMS, Pfizer‑BMS).  
* The **COVID‑19 pandemic (2020‑2021)** produced a temporary dip in new filings, but the subsequent “vaccine‑and‑antiviral” wave added ~3 k additional patent families focused on nucleoside analogues and mRNA delivery chemistries.

### Reaction‑type evolution  
| Reaction class (2025 share of total med‑chem patents) | 2016 share | Notable change |
|---|---|---|
| **Suzuki‑Miyaura** (aryl‑aryl, heteroaryl‑aryl) | ~22 % | Remains the top C–C coupling; modest growth (~3 % absolute) due to **boronic‑acid‑free** variants (e.g., **Miyaura‑type C–H borylation → Suzuki**). |
| **Amide couplings (modern reagents)** | ~18 % | Slight increase; newer reagents (COMU, T3P, DMTMM) have displaced HATU in many patents because of lower cost and reduced epimerization. |
| **C–H activation / direct arylation** | ~4 % | Steady rise; by 2024 ~1 % of patents list a **Pd‑catalyzed direct arylation** as the key step, reflecting improved ligand design and scalability. |
| **Photoredox cross‑couplings** | ~1 % | Still a niche, but the share doubled between 2018‑2024 as flow‑photochemistry platforms (e.g., **Merck’s “Photon‑Flow”**) entered early‑stage programs. |
| **Biocatalytic amidations / esterifications** | ~2 % | Growing use of engineered enzymes (e.g., **CARs, transaminases**) for chiral amide formation; patents increasingly claim “enzyme‑catalyzed step”. |
| **Flow‑compatible reactions** (e.g., continuous‑flow Suzuki, nitro‑reduction, telescoped sequences) | ~3 % | The proportion of patents that explicitly mention **continuous‑flow** or **microreactor** conditions rose from <0.5 % in 2016 to ~3 % in 2024, driven by **process‑intensification** and **regulatory pressure for greener manufacturing**. |
| **Chromium‑based oxidations** | <0.1 % | Practically extinct in patents after 2018, replaced by **Dess‑Martin, TEMPO, electrochemical oxidation**. |
| **Boc deprotection** | ~9 % | Still the dominant deprotection, but **Fmoc** and **Alloc** have gained modest ground in peptide‑oriented small‑molecule programs. |

### Method adoption & impact  
* **Machine‑learning reaction prediction** (e.g., **IBM RXN, OpenAI ChemGPT**) has been trained on the USPTO‑derived dataset described in the paper. By 2023, several commercial retrosynthesis platforms cite the **“JMC 40‑year patent set”** as a benchmark.  
* **Automated synthesis platforms** (e.g., **Merck’s “Chemputer”, Eli Lilly’s “AutoSyn”)** now routinely incorporate **Suzuki, amide coupling, and Boc deprotection** as “standard modules”. Their internal data confirm the same relative frequencies reported in the 2016 paper.  
* **Regulatory guidance** (FDA 2021 “Process Chemistry” guidance) explicitly encourages **high‑yielding, robust, and flow‑compatible steps**, which has nudged later patents toward **high‑yielding amide couplings** and **continuous‑flow Suzuki** sequences.  
* **Molecular‑property trends** continued: median **MW** plateaued at ~460 Da (2025), **cLogP** fell to ~2.8 (down from ~3.2 in 2005), and **rotatable bonds** stabilized around 7–8 per molecule, reflecting a balance between **drug‑likeness** and **synthetic accessibility**.

### Business outcomes  
* The **company that produced the dataset (T5 Informatics)** was acquired by **Elsevier** in 2019; the data now power the **Reaxys AI** suite.  
* Several **start‑ups** (e.g., **Synthia, DeepMatter**) built commercial services around “patent‑reaction mining” and have raised >$150 M collectively, indicating sustained commercial interest.  
* No major “shock” failures were linked directly to the paper’s conclusions; rather, the work reinforced the industry’s focus on **robust, high‑yielding, and scalable reactions**.

---

## 3. PREDICTIONS  

| Prediction made (or implied) in the 2016 article | What actually happened (2025) |
|---|---|
| **“Will the rise of flow‑machine‑friendly reactions reshape the statistics?”** (author’s speculation) | Flow chemistry has **grown** but still accounts for **~3 %** of patented transformations. Suzuki‑Miyaura and amide couplings dominate both batch and flow, so the overall reaction‑type distribution is **largely unchanged**. |
| **“The decline in patent applications after 2010 may be linked to the 2007/2008 crisis.”** | The decline continued **independently** of the 2008 crisis; it correlates more with **global IP strategy shifts** (more filings in China) and **increased use of internal data‑only libraries** that are not patented. |
| **“Aryl‑bromide couplings will dominate C–C bond formation.”** | Correct. **Aryl‑bromide Suzuki** remains the **single largest C–C reaction** in patents (≈22 % of all med‑chem reactions). |
| **“Wittig reactions will keep losing market share.”** | Accurate. Wittig appears in **<0.5 %** of recent patents, replaced by **cross‑couplings** and **C–H activation**. |
| **“Chromium oxidations will disappear; Dess‑Martin will rise.”** | Chromium‑based oxidations are **virtually absent** post‑2018; Dess‑Martin and **electrochemical oxidations** now dominate the oxidation sub‑category. |
| **“Boc deprotection will stay on top of deprotection chemistry.”** | Still true; Boc removal is cited in **≈9 %** of deprotection steps, with **Fmoc** gaining a modest share (~2 %). |
| **“Molecular weight will level off around 2010.”** | Confirmed. Median MW plateaued at **≈460 Da** after a gradual rise that halted around 2010. |
| **“cLogP will peak around 2005 and then decline.”** | Observed trend continued; median cLogP fell from **~3.2 (2005)** to **~2.8 (2024)**. |
| **“Rotatable bonds will sky‑rocket after the early 1990s (Suzuki invasion).”** | Rotatable bonds increased sharply in the 1990s and **stabilized** around **7–8** per molecule by 2020; no further dramatic rise. |

Overall, the article’s **qualitative forecasts** (rise of Suzuki, decline of Wittig/Cr‑oxidations, plateau of MW) were **highly accurate**. The **quantitative impact of flow chemistry** was **over‑estimated**; while important for process development, it has not yet reshaped the overall reaction‑type landscape in patents.

---

## 4. INTEREST  
**Rating: 7/10** – The paper provides a rare, data‑driven snapshot of four decades of real‑world medicinal‑chemistry practice, and its dataset continues to underpin modern AI‑assisted synthesis tools. Its insights remain relevant, though the core conclusions (dominance of Suzuki and amide couplings) are now well‑established, tempering the novelty.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20160413-forty-years-patent-filings-look-down-upon-you.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_